Study of ORJ-001 for the Treatment of IPF

November 16, 2026 updated by: Oorja Bio, Inc.

A Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerability (Part A), and Efficacy (Part B), of ORJ-001 in Patients With Idiopathic Pulmonary Fibrosis (ORBIT-IPF)

ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This Phase 2a/2b, randomized, double-blind, placebo-controlled, multicenter study will evaluate the safety, tolerability, and efficacy of ORJ-001 administered subcutaneously twice weekly in adults with IPF. The study consists of two parts. Part A will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of two dose levels of ORJ-001 compared with placebo over 12 weeks of treatment. Data from Part A will be reviewed by an independent Data Monitoring Committee to select the dose for Part B. Participants in Part A will not continue into Part B; Part B will enroll a separate cohort of participants. Part B will evaluate the efficacy of the selected ORJ-001 dose compared with placebo, with the primary efficacy endpoint being change from baseline in forced vital capacity (FVC) at Week 12. Secondary and exploratory assessments include percent predicted FVC, time to acute IPF exacerbation, respiratory hospitalization or death, patient-reported outcomes, pharmacokinetics, and biomarkers of fibrosis. Adults aged 40 years or older with confirmed IPF and adequate pulmonary function who are receiving stable antifibrotic standard-of-care therapy, or who have previously discontinued such therapy due to tolerability or lack of response, may be eligible to participate.

Study Type

Interventional

Enrollment (Estimated)

95

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Recruiting
        • University of Alabama at Birmingham
        • Principal Investigator:
          • Tejaswini Kulkarni, MD
    • Florida
      • Doral, Florida, United States, 33172
        • Recruiting
        • Innova Pharma Research, LLC
    • Pennsylvania
      • DuBois, Pennsylvania, United States, 15801
        • Recruiting
        • Clinical Research Associates of Central PA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  1. Male or female participants aged ≥ 40 years when signing informed consent
  2. Non-smoker or ex-smoker who has stopped smoking for > 6 months prior to signing informed consent
  3. Diagnosis of IPF, as defined by 2022 international guidelines and confirmed by centrally adjudicated finding of a definite or probable UIP pattern on HRCT of the chest. The HRCT may be performed at screening or, if available, a historical HRCT obtained within 12 months from screening may be submitted for central review
  4. FVC of at least 45% of the predicted value and a DLCO, corrected for the hemoglobin level, of at least 25% and no greater than 90% of the predicted value. Note: Each test (FVC and DLCO) may be repeated once after a minimum of 24 hours if the initial result is deemed unreliable by the investigator
  5. If receiving SOC antifibrotic therapy, participants must be on a stable regimen of a single approved therapy for at least 60 days prior to the screening visit. Participants who have discontinued SOC antifibrotic therapy due to tolerability or lack of response may be enrolled after at least 30 days of discontinuing the SOC antifibrotic therapy.
  6. Negative serum pregnancy test in women of childbearing potential at the screening visit

Key Exclusion Criteria:

  1. Participants who are treatment-naïve with respect to SOC antifibrotic therapies
  2. Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  3. Major surgery (including joint surgery) within 8 weeks from screening, or planned major surgery within 4 months following randomization
  4. Presence of one or more significant concurrent medical conditions that may affect the outcome of the study per investigator judgement
  5. Participants with relevant airway obstruction, defined as pre bronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) ratio < 0.7 at screening
  6. Lower respiratory tract infection requiring antibiotics within 4 weeks from screening, or during the screening period (may be rescreened following recovery)
  7. Acute IPF exacerbation within 3 months from screening, or during the screening period
  8. Receiving more than 15 mg per day of prednisone during screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part A: ORJ-001 400 mg

Participants receive ORJ-001 400 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (400 mg:200 mg:placebo).

ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

Matching placebo administered by subcutaneous injection twice weekly.

Experimental: Part A: ORJ-001 200 mg

Participants receive ORJ-001 200 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (active:active:placebo).

ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

Matching placebo administered by subcutaneous injection twice weekly.

Placebo Comparator: Part A: Placebo

Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks.

Matching placebo administered by subcutaneous injection twice weekly.

Experimental: Part B: ORJ-001 (Selected Dose)

Participants receive the ORJ-001 dose selected based on Part A safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy data, administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Participants are randomized 1:1 to ORJ-001 or placebo.

ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

Matching placebo administered by subcutaneous injection twice weekly.

Placebo Comparator: Part B: Placebo

Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks.

Matching placebo administered by subcutaneous injection twice weekly.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part A: Safety and Tolerability of ORJ-001: Number of Participants with Treatment-Related Adverse Events (TEAEs)
Time Frame: From first dose through Safety Follow-up Visit, up to 12 weeks.

Number of participants experiencing at least one treatment-emergent adverse event.

From first dose through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Severity of Treatment-Emergent Adverse Events (TEAEs)
Time Frame: From first dose through Safety Follow-up Visit, up to 12 weeks.

Severity of treatment-emergent adverse events as graded according to CTCAE v6.0.

From first dose through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Systolic Blood Pressure
Time Frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in systolic blood pressure measured in millimeters of mercury (mmHg).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Body Temperature
Time Frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in body temperature measured in degrees Celsius (°C).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Heart Rate
Time Frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in heart rate measured in beats per minute (bpm).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Respiratory Rate
Time Frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in respiratory rate measured in breaths per minute.

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Oxygen Saturation
Time Frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.

Change from baseline in oxygen saturation measured as percentage (% SpO₂).

Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Corrected QT Interval
Time Frame: Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.

Change from baseline in corrected QT interval (QTc) measured by electrocardiogram (ECG) in milliseconds (ms).

Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.
Part B: Change from Baseline in Forced Vital Capacity (FVC)
Time Frame: Baseline to Week 12

Change from baseline in FVC measured by spirometry at Week 12.

Baseline to Week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part B: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC%)
Time Frame: Baseline to Week 12.

Change from baseline in percentage of predicted FVC measured by spirometry at Week 12.

Baseline to Week 12.
Part B: Time to Acute Exacerbation of IPF, Hospitalization for a Respiratory Cause, or Death
Time Frame: Up to Week 12.

Time, in days, to first occurrence of acute IPF exacerbation, hospitalization for a respiratory cause, or death.

Up to Week 12.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Oorja Bio Medical Director, Oorja Bio, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

March 1, 2029

Study Registration Dates

First Submitted

September 21, 2026

First Submitted That Met QC Criteria

October 6, 2026

First Posted (Actual)

October 9, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ORJ-001-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.